Latest Content

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Key schizophrenia facts: early warning signs, brain changes, treatment limits—and how AI could reveal biomarkers for more personalized care.

Federal fast-tracks boost psychedelic research.

A new report shows private practice clinicians deliver over 113 million sessions of mental health care, making up the majority of outpatient care.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

Anosognosia drives untreated schizophrenia into homelessness and jail. Here's why civil care fails and how structured treatment can decrease the number of arrests.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Leading psychiatric organizations respond to federal push for deprescribing.

Renaming borderline personality disorder fails to address the condition's complexity; keeping the term preserves key clinical meaning, including structural traits and stress-related psychotic symptoms.

Psilocybin therapy shows fast, lasting relief for depression; clinicians discuss trial hurdles and emerging promise for PTSD and addiction in this podcast.